Nabi Biopharmaceuticals, Inc.

Nabi

Nanobio Corporation

Bluewillow Biologics, Inc.

Washington University

Glaxosmithkline Biologicals Sa

Ali Ibrahim Fattom

Robert B Naso

Sofiane Ennifar

Tarek Hamouda

James R Baker, Jr

Vira Bitko

Viliam Pavliak

D Craig Wright

Ramesh K Sood

Sara E Shepherd

Jakub Simon

Atulkumar Induprasad Patel

Jr Baker James R

Douglas M Smith

Paul D Kessler

Zuzana Kossaczka

Matthew W Kalnik

Matthew Hohenboken

Raafat Fahim

Shabaana Abdul Khader

Leslie Hudson

Mushtaq Ahmed

Walter W Karakawa

Walter W Karakawa, Deceased

Nicolas Lukacs

Jawad Sarwar

Kimberly L Taylor

James R Baker

The present disclosure relates to compositions and methods for inducing an immune response to a composition of the invention in a subject. Additionally, the present disclosure generally relates to methods for screening for immune response to a composition of the invention.

Nanoemulsion and methods of use thereof

The present application relates to the field of human immunology, in particular, a herpes simplex virus (HSV) vaccine. The subunit vaccine composition comprises isolated surface glycoproteins from herpes simplex viruses, fusion proteins or fragments thereof mixed in varied combination with a nanoemulsion, which is a potent immune enhancer.

Herpes simplex virus nanoemulsion vaccine

The present application relates to the field of immunology, in particular, a vaccine composition of respiratory syncytial virus (RSV) surface proteins, Fusion (F) and Glycoprotein (G) proteins subunit vaccine preferentially mixed with the immune cell targeting and enhancer, nanoemulsion to induce a protective immune response and avoid vaccine-induce disease enhancement.

Nanoemulsion respiratory syncytial virus (RSV) subunit vaccine

The present invention relates to RSV vaccines and methods for inducing an immune response to RSV in a subject comprising administering an RSV vaccine.

Human respiratory syncytial virus vaccine

Described are smoking cessation devices and kits for determining an advantageous time for a subject to quit smoking, and/or for extending the duration of smoking abstinence, based on serum levels of anti-nicotine antibodies. Related methods are also described.

Smoking cessation kit and method

Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(&#x2212;) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.

Hapten-carrier conjugates for treating and preventing nicotine addiction

A method of preventing or treating staphylococcal bacterial infection in an individual is disclosed. A vaccine based on a conjugate of PS1 polysaccharide antigen can be used for active protection in individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure. Alternatively, antibodies raised in response to the antigen can be used to treat or to provide passive protection to individuals. The method can be used in a population of patients at risk for infection by various species ofor various types of

Method of protecting against staphylococcal infection

A negatively-chargedantigen contains amino acids and a N-acetylated hexosamine as a major carbohydrate component. The antigen is common to many coagulase-negative strains of, including, andstrains that carry the antigen include many clinically significant strains of. The antigen and antibodies to the antigen are useful in kits and assays for diagnosinginfection. Vaccines of the antigen and of whole cells that carry the antigen also are disclosed.

[object Object]

andglycoconjugate vaccines are disclosed for use in preventing or treating bacterial infection in an immune-compromised individual. Such vaccines contain an immunocarrier and a conjugate of a polysaccharide or glycopeptide surface antigen from a clinically-significant bacterial strain. The vaccines can be used for active protection in immune-compromised individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure.

Glycoconjugate vaccines for use in immune-compromised populations

A majority ofandclinical isolates fall into two groups and three groups, respectively. Distinct antigens are associate with each of the five groups. Theantigens are readily obtained from strains ofand, and can elicit production of protective antibodies. Accordingly, the antigens are useful for vaccines which protect against infection by clinically significant (pathogenic)isolates. The antigens and antibodies generated to the antigens are also useful in diagnostic assays.

Compositions and kits comprising combinations of &#x3b2;-glucans and specific immunoglobulins are disclosed. The compositions and kits are useful in methods of preventing or treating infection by a pathogenic microorganism, in which &#x3b2;-glucan is administered to a subject, and specific antibodies to a pathogenic microorganism are introduced into the subject.

Compositions of &#x3b2;-glucans and specific antibodies

Growing community of inventors

Rockville, MD, United States of America

Ali Ibrahim Fattom